This round is no longer accepting investments, but hundreds just like it are live now.

Log In

GET A PIECE OF ECLIPSE DIAGNOSTICS

Preventing Stroke At Home

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$171,750 Raised

REASONS TO INVEST

ABOUT

HEADQUARTERS
​WeWork Pacific Design Center 750 N San Vicente Blvd
​Los Angeles, CA ​90069

TEAM

Luka Fajs
Luka Fajs
President, CEO, Director

Luka comes from Slovenia and holds a PhD in Medical Microbiology from University of Ljubljana, Slovenia. Before starting the Company, he was doing research and clinical laboratory diagnostics of hemorrhagic fevers, biothreats and other infectious diseases. He spent a lot of time in the field, helping doctors and nurses in low-income countries to set up and improve their diagnostic preparedness. During his work, he saw first-hand the drawbacks of the existing medical diagnostics system that is mostly centralized, capital-intensive and many people do not have adequate access to it. That was the motivation to join Prof. Robert’s laboratory in Singapore where he took over the fundraising and startup activities of the technology. He continued as CEO of Biosensorix and helped secure early funding and directed the research and development activities. He is a passionate entrepreneur with deep knowledge of diagnostics, user expectations, and basic science. Jan 2014 - Dec 2014: Post-doc at Institute of Microbiology and Immunology, University of Ljubljana, Slovenia - research and clinical diagnostics of viral hemorrhagic fevers and other zoonoses Jan 2015 - Dec 2016: Post-doc at Nanyang Technological University, Singapore - research and development of diagnostic and environmental monitoring platforms Nov 2015 - present: cofounder, CEO and Director of Biosensorix Pte. Ltd., Singapore - research and development of medical devices for rapid detection and quantification of disease biomarkers Feb 2018 - present: cofounder, president, CEO and Director of Eclipse Diagnostics Inc., USA - research and development of medical devices for rapid detection and quantification of disease biomarkers

Prof. Robert S. Marks
Prof. Robert S. Marks
Chief Scientist, Director

Prof. Dr. Robert S. Marks is the co-inventor of the technological platform and is a renowned expert and key opinion leader in the field of biosensors. He is a Full Professor at the Ben-Gurion University of the Negev, Israel, at the Department of Biotechnology Engineering, The National Institute for Biotechnology in the Negev and the Ilse Kats Centre for Nanotechnology. He was a Visiting Scientist in the NTU-MSE, and was a program coordinator for the NRF CREATE program "Nanomaterials for Water and Energy Management". Robert has previously co-founded Biosensing Technologies Ltd, Biopixel Ltd and Polyrizon Ltd. He will be assisting with advising the development of the next generation prototype and establishing the business collaboration with potential partners. Prof. Marks has extensive experience in development of biosensors. He is the Editor-in-Chief of a 2007 2-volume Wiley Handbook in Biosensors and Biochips and a 2014 Viral Diagnostics book for virus detection. He is the author of 150+ papers (H-index 27), and numerous chapters. He has 4 issued patents as well as a dozen filed. 2011-present: Full Professor at Avram and Stella Goldstein-Goren Department of Biotechnology Engineering, Ben-Gurion University of the Negev, Israel Jan 2012 - Dec 2016: Visiting Professor at Nanyang Technological University, Singapore July 2011 - Jun 2016: Coordinator at NRF (National Research Foundation) CREATE Center for Nanomaterials for Energy and Water Management, Singapore Nov 2015 - present: cofounder and Director of Biosensorix Pte. Ltd., Singapore - research and development of medical devices for rapid detection and quantification of disease biomarkers Feb 2018 - present: cofounder and Director of Eclipse Diagnostics Inc., USA - research and development of medical devices for rapid detection and quantification of disease biomarkers

Tina Semolic

Tina Semolic

Head of Marketing

Marketing advisor at Biosensorix Pte. Ltd. Previously at Adglow.com (clients: Prada, Miu Miu, Moschino, Pinko, Max Mara, Armani ect.), Httpool.com (over 50 clients: Generali insurance, Mercedes, Audi, STO - Slovenian touristic org. ect.), Adroll.com (Head of Business Development SMB) Facebook.com (over 500 clients: Adidas, Nike, Ferrari, illy, Morellato, Fossil, Head, Hugs ect.)

Ðina Mandic

Ðina Mandic

Social Media Marketing Manager

Currently at Đina's Real estate agency. Đina is an angel investor and experienced salesperson and marketer with a passion for social media and PR.

TERMS

Eclipse Diagnostics
Overview
PRICE PER SHARE
$10
DEADLINE
Dec 5, 2018
VALUATION
$10M
FUNDING GOAL
$10k - $1.07M
Breakdown
MIN INVESTMENT
$500
MAX INVESTMENT
$107,000
MIN NUMBER OF SHARES OFFERED
1,000
MAX NUMBER OF SHARES OFFERED
107,000
OFFERING TYPE
Equity
SHARES OFFERED
Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

Most Recent Fiscal Year-End

Prior Fiscal Year-End

Total Assets

$0

$0

Cash & Cash Equivalents

$0

$0

Accounts Receivable

$0

$0

Short-Term Debt

$0

$0

Long-Term Debt

$0

$0

Revenue & Sales

$0

$0

Costs of Goods Sold

$0

$0

Taxes Paid

$0

$0

Net Income

$0

$0

Perks*

All investors

Regular updates on our technology progress

$2,000+

Exclusive content and regular company updates -

Canabinox test prototype

$5,000+

Your place on the Technology Ambassadors Page of the website - Exclusive content and frequent company

updates –

Canabinox test prototype

1-year 'Casual' subscription to the Canabinox testing - FREE

$10,000+

Your place on the Technology Ambassadors Page of the website - Exclusive content and regular company

updates –

Canabinox test prototype

Invitation to our annual company VIP events.

1-year 'Basic' subscription to the Canabinox testing - FREE

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments and salaries; Any expense labeled “Administration Expenses” that is not strictly for administrative purposes; Any expense labeled “Travel and Entertainment”; Any expense that is for the purposes of inter-company debt or back payments.

PRESS

Article Image
New Diagnostic Device Designed to Prevent Stroke at Home

Article Image
PREVENTING STROKE AT HOME

Exclusive interview for SPINOFF.COM with Dr. Luka Fajs, Eclipse Diagnostics Inc., CEO, about blood-testing medical platform

ALL UPDATES

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Eclipse Diagnostics.

JOIN THE DISCUSSION

0/2500

RP
Robin Perkins

3 months ago

It's been awhile since we've heard about our investment in this company. The company website appears to have been re-purposed. I'd like to get an update from the team about the direction this company is moving. Have we generated any revenue? Has our investment been profitable?

0

0

RP
Robin Perkins

a year ago

I would like to see how our investment in Eclipse Diagnostics is doing.

0

0

PA
Prasanna Airody

2 years ago

What is the current status of the company?

0

0

JH
John Harrington

5 years ago

Eclipse has ended the Start Engine Campaign. Does that mean it is going to be listed on an exchange as an IPO ?

1

0













SI
Sheila Iverson

5 years ago

Who do you think can afford a minimum $60 per month subscription?! If you want to help people, then help them across the range of incomes. Help the poor, help the working clasd poor and all those in between who can not afford to pay $60 a month to be stroke-screened.

1

0













rr
rob rog

5 years ago

Greetings, Nice business model, how many accredited investors vs non-accredited have invested?

1

0













MB
Matthew Burrow

5 years ago

Hello, I am interested in investing in Eclipse. I did read some studies about stroke biomarkers and wanted to know if you can refer me to more specific studies more pertinent to your product.

11

0













AJ
Alan Jacobson

5 years ago

Hi, interesting presentation. Great team. I have some questions, thanks in advance for your answers: 1. Is the license to the patent in perpetuity, and with no possible outs (and would any related patents definitely also have exclusive licenses forever)? 2. Above you seem to say that FDA approval will take both one year and three years/ Which one is correct? And related, would FDA approval only be for the stroke biomarker, and would it therefore take another 1-3 years for approval of any other biomarkers? 3. Can you talk about your finances, particularly cash burn and runway? 4. How much of the core team's time is being dedicated to this particular product? I am including the CEO, Chief Scientist and Marketing team (the latter of whom seem to have successful careers in other areas, which is great, but how much of their time do you get?) Thanks!

1

0













AJ
Alan Jacobson

5 years ago

Hi Tina, excellent answers. It all seems quite reasonable for a biopharm startup. I think I'm in. Just three quick follow-ups: 1. What would be the potential timeline going forward, as far as development and FDA approval, of the use of your technology for other biomarkers for other medical issues? Does the exclusive license cover any and all uses of that IP on biomarker technology (beyond stroke)? Finally, what do you feel needs to happen in the next year - what accomplishments - so that you can be confident that a 5 mil raise in 2019 is realistic? Thanks again!

1

0













TS
Tina Semolic

Eclipse Diagnostics

6 years ago

Hi Charles You are correct that a portion diabetics would not be able to absorb the additional yearly testing cost and that insurance should cover this. We have not yet engaged in discussion with them but this is one of our key activities in the following months. The key here is that we are able to reduce out manufacturing cost to a minimum in the following 12-18months and that will enable our positioning to the insurers to cover the cost of testing especially with regard to the high cost associated with treatment and rehabilitation of stroke patients. We are collaborating and have interviewed several doctors that support our case. However, final endorsement will only come once we have more clinical validation data (clinical validation will follow the first development stage). We plan to sell the device as OTC.

0

0

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

RAISED
$171,750
INVESTORS
94
MIN INVEST
$500
VALUATION
$10M

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.

www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.
Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRASIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.
By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information

(800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.

StartEngine Marketplace

The availability of company information does not indicate that the company has endorsed, supports, or otherwise participates with StartEngine.

None of the information displayed on or downloadable from www.startengine.com (the 'Website') represents a recommendation, offer, or solicitation of an offer to buy or sell any security. It also does not constitute an offer to provide investment advice or service. StartEngine does not (1) make any recommendations or otherwise advise on the merits or advisability of a particular investment or transaction, or (2) assist in the determination of fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.

All investment opportunities are based on indicated interest from sellers and will need to be confirmed.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks, and you should complete your own independent due diligence regarding the investment. This includes obtaining additional information about the company, opinions, financial projections, and legal or other investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment.

StartEngine Marketplace (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC. StartEngine Bulletin Board ("SE BB") is a bulletin board platform that advertises interest in shares of private companies that previously executed Reg CF or Reg A offerings. SE BB enables shareholders to communicate interest in potential sales of shares in private companies and investors to discover, review, and potentially invest in private companies. As a bulletin board platform, SE BB provides a venue for investors to access information about private company offerings and connect with potential sellers. SE BB is distinct and separate from StartEngine Secondary (“SE Secondary”), which is an SEC-registered Alternative Trading System (ATS) operated by SE Primary. SE Secondary facilitates the trading of securities by matching orders between buyers and sellers and facilitating executions of trades on the platform. While a security may be displayed on the bulletin board, these securities will be subject to certain restrictions which may prevent the ability to buy and sell these securities in a timely manner, if at all. Even if a security is qualified to be displayed on the bulletin board, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.